BioLineRx (BLRX) Net Cash Flow (2013 - 2026)

BioLineRx's Net Cash Flow history runs 13 years deep, the most recent figure standing at -$4.8 million for Q4 2025.

• In Q4 2025, Net Cash Flow fell 433.03% year-over-year to -$4.8 million; the TTM figure through Dec 2025 stood at -$7.7 million (down 225.59% YoY), while the FY2025 annual figure was -$7.7 million, down 225.59% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$4.8 million, down from $651000.0 in the prior quarter.
• The five-year high for Net Cash Flow was $3.9 million in Q2 2024, with the low at -$4.8 million in Q4 2025.
• The 5-year median for Net Cash Flow is -$1.1 million (2022), against an average of -$676400.0.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 218.34% in 2024, then tumbled 433.03% in 2025.
• BioLineRx's Net Cash Flow stood at -$1.3 million in 2021, then plunged by 85.42% to -$2.5 million in 2022, then plunged by 48.46% to -$3.7 million in 2023, then soared by 139.25% to $1.4 million in 2024, then sank by 433.03% to -$4.8 million in 2025.
• Business Quant data shows BLRX's Net Cash Flow at -$4.8 million in Q4 2025, $651000.0 in Q3 2025, and -$2.3 million in Q2 2025.